<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>53(5)</volume><submitter>Zhang Y</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>The relationship between ischemic stroke (IS) and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity is still unclear, and there is a dearth of stratified research on the relationship between Lp-PLA2 activity and different IS subtypes. Therefore, Mendelian randomization (MR) was used in this study to examine the relationship between genetically proxied Lp-PLA2 activity and the risks of IS and its subtypes.&lt;h4>Methods&lt;/h4>Based on information from a meta-analysis of genome-wide association studies, which included 13,664 European people, five single nucleotide polymorphisms related to Lp-PLA2 activity were chosen as instrumental variables. Summary statistics information about the MEGESTROKE consortium with the European group (40,585 cases and 406,111 controls) include any IS (AIS; n = 34,217), large-artery stroke (LAS; n = 4,373), cardioembolic stroke (CES; n = 7,193), and small-vessel stroke (SVS; n = 5,386). In order to determine the causal relationships between Lp-PLA2 activity and IS as well as its subtypes, the inverse-variance-weighted (IVW) approach was chosen as the primary analysis. Significant estimates were then tested by sensitivity analysis to rule out heterogeneity and pleiotropy.&lt;h4>Results&lt;/h4>IVW showed that Lp-PLA2 activity was causally associated with LAS (odds ratio = 3.25, 95% confidence interval = 1.65-6.41, p = 0.0007) but not with other subtypes of stroke. Sensitivity analysis for causal estimates between Lp-PLA2 activity and LAS showed no significant heterogeneity or pleiotropy.&lt;h4>Conclusions&lt;/h4>These MR analyses support a causal effect of Lp-PLA2 activity on LAS but not on AIS, CES, or SVS, which suggests that serum Lp-PLA2 activity might be a biomarker for prediction of LAS.</pubmed_abstract><journal>Cerebrovascular diseases (Basel, Switzerland)</journal><pagination>579-587</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11446331</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Causal Effect of Lipoprotein-Associated Phospholipase A2 Activity on Ischemic Stroke: A Mendelian Randomization Study.</pubmed_title><pmcid>PMC11446331</pmcid><pubmed_authors>Ji X</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Zhou C</pubmed_authors><pubmed_authors>Gao Y</pubmed_authors><pubmed_authors>Wu D</pubmed_authors><pubmed_authors>Jiang M</pubmed_authors><pubmed_authors>Zhou Y</pubmed_authors><pubmed_authors>Li M</pubmed_authors><pubmed_authors>Xu Y</pubmed_authors><pubmed_authors>Liu G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Causal Effect of Lipoprotein-Associated Phospholipase A2 Activity on Ischemic Stroke: A Mendelian Randomization Study.</name><description>&lt;h4>Background&lt;/h4>The relationship between ischemic stroke (IS) and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity is still unclear, and there is a dearth of stratified research on the relationship between Lp-PLA2 activity and different IS subtypes. Therefore, Mendelian randomization (MR) was used in this study to examine the relationship between genetically proxied Lp-PLA2 activity and the risks of IS and its subtypes.&lt;h4>Methods&lt;/h4>Based on information from a meta-analysis of genome-wide association studies, which included 13,664 European people, five single nucleotide polymorphisms related to Lp-PLA2 activity were chosen as instrumental variables. Summary statistics information about the MEGESTROKE consortium with the European group (40,585 cases and 406,111 controls) include any IS (AIS; n = 34,217), large-artery stroke (LAS; n = 4,373), cardioembolic stroke (CES; n = 7,193), and small-vessel stroke (SVS; n = 5,386). In order to determine the causal relationships between Lp-PLA2 activity and IS as well as its subtypes, the inverse-variance-weighted (IVW) approach was chosen as the primary analysis. Significant estimates were then tested by sensitivity analysis to rule out heterogeneity and pleiotropy.&lt;h4>Results&lt;/h4>IVW showed that Lp-PLA2 activity was causally associated with LAS (odds ratio = 3.25, 95% confidence interval = 1.65-6.41, p = 0.0007) but not with other subtypes of stroke. Sensitivity analysis for causal estimates between Lp-PLA2 activity and LAS showed no significant heterogeneity or pleiotropy.&lt;h4>Conclusions&lt;/h4>These MR analyses support a causal effect of Lp-PLA2 activity on LAS but not on AIS, CES, or SVS, which suggests that serum Lp-PLA2 activity might be a biomarker for prediction of LAS.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2026-06-01T10:05:20.079Z</modification><creation>2025-04-04T08:22:16.787Z</creation></dates><accession>S-EPMC11446331</accession><cross_references><pubmed>38113871</pubmed><doi>10.1159/000535286</doi></cross_references></HashMap>